LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

NCT07391566 | Not Yet Recruiting Phase 1

• 1 other identifier: LY01024/CT-CHN-102
• Study Type: interventional
• Target: 99
• Locations: 1 country
• Sites: 1

Brief Summary

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

Conditions

Metastatic Colorectal Cancer (mCRC)

Outcome Measures

Primary Outcomes (4)

• Phase Ib: Dose-limiting toxicities (DLTs)

  From the first dose of study drug treatment through Cycle 1 (28 days)

• Phase Ib: Maximum tolerated dose (MTD)

  From the first dose of study drug treatment through Cycle 1 (28 days)

• Phase 1b: Recommended Phase 2 Dose (RP2D)

  From the first dose of study drug treatment through Cycle 1 (28 days)

• Phase 2: Overall response rate (ORR)

  Approximately 2 years

Secondary Outcomes (11)

• Phase 1b: Overall response rate (ORR)

  Approximately 2 years

• Duration of response (DOR)

  Approximately 2 years

• Disease control rate (DCR)

  Approximately 2 years

• Progression-free survival (PFS)

  Approximately 2 years

• Overall survival (OS)

  Approximately 2 years

Study Arms (3)

LPM6690176 24 mg/m2

EXPERIMENTAL

LPM6690176 capsules administered 24 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

Drug: LPM6690176; Biological: Bevacizumab; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

LPM6690176 36 mg/m2

EXPERIMENTAL

LPM6690176 capsules administered 36 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

Drug: LPM6690176; Biological: Bevacizumab; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

LPM6690176 42 mg/m2

EXPERIMENTAL

LPM6690176 capsules administered 42 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

Drug: LPM6690176; Biological: Bevacizumab; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Interventions

LPM6690176 DRUG

LPM6690176 orally.

LPM6690176 24 mg/m2; LPM6690176 36 mg/m2; LPM6690176 42 mg/m2

Bevacizumab BIOLOGICAL

Bevacizumab intravenously

LPM6690176 24 mg/m2; LPM6690176 36 mg/m2; LPM6690176 42 mg/m2

FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) DRUG

FOLFIRI intravenously

LPM6690176 24 mg/m2; LPM6690176 36 mg/m2; LPM6690176 42 mg/m2

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to provide a signed informed consent;
• Age ≥ 18 years and ≤ 75 years, both male and female;
• Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;
• Prior therapies for colorectal cancer:
• (1 ) For phase 1b patients: who have failed or intolerable to prior first-line therapy; (2) For phase 2 patients: who have not received prior systemic therapy for metastatic colorectal cancer.
• \. At least one measurable lesion according to RECIST 1.1 criteria; 6. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1; 7. Life expectancy≥ 6 months; 8. Adequate bone marrow and organ function; 9. Negative pregnancy test for women of childbearing potential. patients of childbearing potential should take effective contraceptive measures during study drug treatment and until 6 months after initiation of investigational product.

You may not qualify if:

• Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) who are suitable for immune checkpoint inhibitor therapy as assessed by the investigator;
• Malignant tumors other than mCRC within 5 years before signing the informed consent;
• Patients who did not recover from the AE of previous anti-tumor treatment to ≤ Grade 1;
• Patients with body cavity effusion requiring local treatment or poorly controlled effusion;
• Symptomatic brain metastasis, history of spinal cord compression or meningeal metastasis;
• Underwent other therapeutic surgery other than diagnosis, biopsy, drainage, or expected to require major surgery during the study, or had unhealed wound, ulcer or fracture.
• Current or previous uncontrolled concomitant non-gastrointestinal disease including, but not limited to myocardial infarction, unstable angina, coronary artery/peripheral artery bypass grafting, heart failure, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, serious arrhythmia, current uncontrolled hypertension, previous history of hypertensive crisis or hypertensive brain disease, tumor invasion into major blood vessels, interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis, reversible posterior leukoencephalopathy syndrome (RPLS), etc.;
• Current or past presence of the gastrointestinal abnormalities, including but not limited to active peptic ulcer, clinically significant gastrointestinal abnormalities prior to informed consent, active colitis, long-term anticoagulant therapy, antiplatelet therapy, etc.;
• Current or past significant risk of bleeding;
• Use of prohibited medication or therapy within the specified time;
• History of drug abuse or alcoholism;
• Known hypersensitivity to any component of any investigational product;
• Pregnant and lactating women;
• Other conditions that may increase the risk of the study or interfere with study results, in the judgment of the investigator.

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

Beijing Cancer Hospital

Beijing, China

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Bevacizumab; Fluorouracil; Leucovorin; Irinotecan

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Coenzymes; Enzymes and Coenzymes; Camptothecin; Alkaloids

Central Study Contacts

Lin Shen, Doctor

CONTACT

0086-10-88196561; doctorshenlin@sina.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2025
• First Posted: February 6, 2026
• Study Start: March 31, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: February 6, 2026

Record last verified: 2026-02

Locations

CN (1)